Novo Nordisk A/S
NOVO-B
Rankning i aktier
#107
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Aktiekurs
$39.74
Marknadsvärde
$175.38B
Förändring (1 dag)
1.28%
Förändring (1 år)
-25.58%
Land
DK
Handel Novo Nordisk A/S (NOVO-B)
Kategori
Healthcare
Vinst för Novo Nordisk A/S (NOVO-B)
Vinst i Dec 2025 TTM: $20.51B
Enligt de senaste finansiella rapporterna från Novo Nordisk A/S är företagets nuvarande vinst $20.51B. År 2024 hade företaget en vinst på $17.75B, en ökning jämfört med vinsten år 2023 som var $15.50B. Vinsten som visas på denna sida är vinsten före räntor och skatt, även kallad EBIT.
Vinshistorik för Novo Nordisk A/S från 2001 till 2026
Vinst vid slutet av varje år
| År | Vinst | Ändra |
|---|---|---|
| 2026 (TTM) | $20.51B | 0.00% |
| 2025 | $20.51B | 15.55% |
| 2024 | $17.75B | 14.50% |
| 2023 | $15.50B | 55.92% |
| 2022 | $9.94B | 10.02% |
| 2021 | $9.03B | 3.59% |
| 2020 | $8.72B | 19.69% |
| 2019 | $7.29B | -0.35% |
| 2018 | $7.31B | -6.79% |
| 2017 | $7.84B | 15.64% |
| 2016 | $6.78B | 7.06% |
| 2015 | $6.34B | 14.26% |
| 2014 | $5.55B | -7.59% |
| 2013 | $6.00B | 22.00% |
| 2012 | $4.92B | 28.80% |
| 2011 | $3.82B | 16.43% |
| 2010 | $3.28B | 21.42% |
| 2009 | $2.70B | 13.54% |
| 2008 | $2.38B | 10.14% |
| 2007 | $2.16B | 33.54% |
| 2006 | $1.62B | 24.30% |
| 2005 | $1.30B | -5.19% |
| 2004 | $1.37B | 6.85% |
| 2003 | $1.28B | 44.62% |
| 2002 | $888.11M | 23.73% |
| 2001 | $717.79M | 0.00% |
Vinst för liknande företag eller konkurrenter
| Företag | Vinst | Skillnad i vinst | Land |
|---|---|---|---|
| $33.60B | 63.84% |
US
|
|
| $17.74B | -13.50% |
US
|
|
| $8.70B | -57.58% |
US
|
|
| $5.95B | -70.99% |
US
|
|
| $21.39B | 4.31% |
CH
|
